- Home
- QUIK vs BDTX Comparison
QUIK vs BDTX Comparison
Compare QUIK & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QUIK | BDTX |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 116.8M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QUIK | BDTX |
|---|---|---|
| Price | $10.80 | $2.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $11.00 | $9.50 |
| AVG Volume (30 Days) | 186.6K | ★ 545.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | N/A | ★ 0.39 |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | $6.41 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.34 | $1.31 |
| 52 Week High | $10.37 | $4.94 |
Technical Indicators
Market Signals| Indicator | QUIK | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.87 | 64.42 |
| Support Level | $5.96 | $2.45 |
| Resistance Level | N/A | $2.64 |
| Average True Range (ATR) | 0.60 | 0.14 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 97.98 | 94.31 |
Price Performance
Historical ComparisonAbout QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.